Human trials for neurodegenerative disease

Claire M. Kelly; O. J. Handley; A. E. Rosser

doi:10.1007/978-1-60327-931-4_3

Human trials for neurodegenerative disease

Claire M. Kelly^*, O. J. Handley, A. E. Rosser

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

2 Citations (Scopus)

Abstract

The lack of disease-modifying treatments currently available for not just some but most neurodegenerative diseases, including Parkinson's disease, Huntington's disease, and even stroke, helps explain increasing interest in cell-based therapies. One key aim of such treatment is to replace neurons or glia lost as a result of the disease, with a view to the cells integrating functionally within the host tissue in order to reconstruct neural circuitry. Clinical trials using primary human fetal tissue as a cell source commenced in Parkinson's disease (PD) in the 1980s; currently, comparable neural transplantation trials in Huntington's disease are underway. Disappointing results of later controlled trials in PD illustrated not least the vital importance of methodological issues relating to the structure and implementation of clinical trials, and these issues will be considered here in more depth.

Original language	English
Title of host publication	Neural Cell Transplantation
Subtitle of host publication	Methods and Protocols
Editors	Neil Scolding, David Gordon
Pages	33-47
Number of pages	15
DOIs	https://doi.org/10.1007/978-1-60327-931-4_3
Publication status	Published - Jan 2009
Externally published	Yes

Publication series

Name	Methods in Molecular Biology
Volume	549
ISSN (Print)	1064-3745

Keywords

Huntington's disease
Neural transplantation
Parkinson's disease
Stem cell therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-1-60327-931-4_3

Cite this

@inbook{5aef459de0a34064bb3b4fdbe5e6c163,

title = "Human trials for neurodegenerative disease",

abstract = "The lack of disease-modifying treatments currently available for not just some but most neurodegenerative diseases, including Parkinson's disease, Huntington's disease, and even stroke, helps explain increasing interest in cell-based therapies. One key aim of such treatment is to replace neurons or glia lost as a result of the disease, with a view to the cells integrating functionally within the host tissue in order to reconstruct neural circuitry. Clinical trials using primary human fetal tissue as a cell source commenced in Parkinson's disease (PD) in the 1980s; currently, comparable neural transplantation trials in Huntington's disease are underway. Disappointing results of later controlled trials in PD illustrated not least the vital importance of methodological issues relating to the structure and implementation of clinical trials, and these issues will be considered here in more depth.",

keywords = "Huntington's disease, Neural transplantation, Parkinson's disease, Stem cell therapy",

author = "Kelly, {Claire M.} and Handley, {O. J.} and Rosser, {A. E.}",

year = "2009",

month = jan,

doi = "10.1007/978-1-60327-931-4_3",

language = "English",

isbn = "9781603279307",

series = "Methods in Molecular Biology",

pages = "33--47",

editor = "Neil Scolding and David Gordon",

booktitle = "Neural Cell Transplantation",

}

TY - CHAP

T1 - Human trials for neurodegenerative disease

AU - Kelly, Claire M.

AU - Handley, O. J.

AU - Rosser, A. E.

PY - 2009/1

Y1 - 2009/1

N2 - The lack of disease-modifying treatments currently available for not just some but most neurodegenerative diseases, including Parkinson's disease, Huntington's disease, and even stroke, helps explain increasing interest in cell-based therapies. One key aim of such treatment is to replace neurons or glia lost as a result of the disease, with a view to the cells integrating functionally within the host tissue in order to reconstruct neural circuitry. Clinical trials using primary human fetal tissue as a cell source commenced in Parkinson's disease (PD) in the 1980s; currently, comparable neural transplantation trials in Huntington's disease are underway. Disappointing results of later controlled trials in PD illustrated not least the vital importance of methodological issues relating to the structure and implementation of clinical trials, and these issues will be considered here in more depth.

AB - The lack of disease-modifying treatments currently available for not just some but most neurodegenerative diseases, including Parkinson's disease, Huntington's disease, and even stroke, helps explain increasing interest in cell-based therapies. One key aim of such treatment is to replace neurons or glia lost as a result of the disease, with a view to the cells integrating functionally within the host tissue in order to reconstruct neural circuitry. Clinical trials using primary human fetal tissue as a cell source commenced in Parkinson's disease (PD) in the 1980s; currently, comparable neural transplantation trials in Huntington's disease are underway. Disappointing results of later controlled trials in PD illustrated not least the vital importance of methodological issues relating to the structure and implementation of clinical trials, and these issues will be considered here in more depth.

KW - Huntington's disease

KW - Neural transplantation

KW - Parkinson's disease

KW - Stem cell therapy

UR - http://www.scopus.com/inward/record.url?scp=67649364084&partnerID=8YFLogxK

U2 - 10.1007/978-1-60327-931-4_3

DO - 10.1007/978-1-60327-931-4_3

M3 - Chapter

C2 - 19378194

AN - SCOPUS:67649364084

SN - 9781603279307

T3 - Methods in Molecular Biology

SP - 33

EP - 47

BT - Neural Cell Transplantation

A2 - Scolding, Neil

A2 - Gordon, David

ER -

Human trials for neurodegenerative disease

Abstract

Publication series

Keywords

UN SDGs

Access to Document

Other files and links

Cite this